Han Ming-Quan, Su Jin-Mei, Huang Hai-Yin, Long Wei-Hong, Qin Li-Ping, Qin Ping, Liu Wei, Sheng Zhao-Ying
Department of Integrated Traditional Chinese and Western Medicine, Pulmonary Disease Hospital of Shanghai, Shanghai 200433, China.
Zhong Xi Yi Jie He Xue Bao. 2003 Sep;1(3):195-8. doi: 10.3736/jcim20030315.
To evaluate the influence of fewer courses and prolonged intervals of chemotherapy on survival rate of advanced non small cell lung cancer (NSCLC) patients treated by sequential chemo-radiation therapy combined with traditional Chinese medicine (TCM).
From Jan. 2000 to Dec. 2001, 54 untreated advanced NSCLC patients (2 stage IIIa, 18 stage IIIb, 34 stage IV) were treated by sequential chemo-radiation therapy combined with TCM. The courses of chemotherapy were reduced and the intervals of chemotherapy were longer than that of the standard regimen. The efficacy and survival rate were documented and the prognostic factors were analyzed.
Complete remission (CR) was observed in 1 case and partial remission (PR) in 20 cases. The overall objective response rate was 40.4%. Median survival was 15.3 months, 1-, 2- and 3-year survival rate were 53.7%, 28.9% and 9.6% respectively. The median survival of stage III and IV were 21.8 months and 12.5 months respectively. The 1-, 2-, and 3-year survival rates of stage III were 65.0%, 49.5%, 24.7% and that of stage IV were 47.0%, 23.3%, 0%, respectively. The quality of life was improved in most of the patients. Cox's proportional hazards regression showed that improved quality of life and treatment of TCM were the significant prognostic factors of overall survival.
Chemotherapy and radiotherapy combined with TCM is beneficial to extending the interval of chemotherapy, improving the quality of life, and increasing the survival rate of advanced NSCLC patients.
评估减少化疗疗程及延长化疗间隔时间对序贯放化疗联合中医药治疗晚期非小细胞肺癌(NSCLC)患者生存率的影响。
2000年1月至2001年12月,对54例未经治疗的晚期NSCLC患者(2例Ⅲa期、18例Ⅲb期、34例Ⅳ期)采用序贯放化疗联合中医药治疗。化疗疗程减少,化疗间隔时间长于标准方案。记录疗效和生存率并分析预后因素。
观察到1例完全缓解(CR),20例部分缓解(PR)。总客观缓解率为40.4%。中位生存期为15.3个月,1年、2年和3年生存率分别为53.7%、28.9%和9.6%。Ⅲ期和Ⅳ期的中位生存期分别为21.8个月和12.5个月。Ⅲ期的1年、2年和3年生存率分别为65.0%、49.5%、24.7%,Ⅳ期分别为47.0%、23.3%、0%。大多数患者的生活质量得到改善。Cox比例风险回归显示生活质量改善和中医药治疗是总生存的显著预后因素。
化疗、放疗联合中医药有利于延长化疗间隔时间,改善生活质量,提高晚期NSCLC患者的生存率。